MCID: KDN017
MIFTS: 58

Kidney Cancer

Categories: Cancer diseases, Nephrological diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 43 15
Renal Cancer 12 76 29 55
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 73
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 73
Kidney Carcinoma 6
Kidney Neoplasms 44
Renal Carcinoma 73
Kidney Neoplasm 73
Renal Neoplasm 29

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD10 33 C64
ICD9CM 35 189.0
MeSH 44 D007680

Summaries for Kidney Cancer

MedlinePlus : 43 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and lung.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 76 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Benign Neoplasm Kidney Carcinoma in Situ
Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 31.7 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MET
2 clear cell renal cell carcinoma 30.1 MALAT1 MEG3 MET MIR21 MTOR PVT1
3 melanoma 29.5 GAS5 H19 HOTAIR MALAT1 MEG3 MIR191
4 bladder cancer 29.0 GAS5 H19 HIF1A-AS2 HOTAIR MALAT1 MEG3
5 hepatocellular carcinoma 28.0 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
6 prostate cancer 27.4 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
7 multilocular cystic renal neoplasm of low malignant potential 12.0
8 kidney cancer, childhood 11.9
9 kidney carcinoma in situ 11.8
10 hereditary leiomyomatosis and renal cell cancer 11.2
11 functionless pituitary adenoma 11.0 HOTAIR MEG3
12 beckwith-wiedemann syndrome due to imprinting defect of 11p15 11.0 H19 KCNQ1OT1
13 renal cell carcinoma, papillary, 1 11.0
14 triple-receptor negative breast cancer 11.0 HOTAIR MALAT1
15 chromophobe renal cell carcinoma 10.9
16 collecting duct carcinoma 10.9
17 microvascular complications of diabetes 3 10.9 MALAT1 MIR21 PVT1
18 pancreatic neuroendocrine tumor 10.8 MEG3 MTOR
19 gastric cardia adenocarcinoma 10.8 H19 HOTAIR MEG3
20 esophagus squamous cell carcinoma 10.8 HOTAIR MEG3
21 birt-hogg-dube syndrome 10.8
22 congenital mesoblastic nephroma 10.8
23 malignant pleural mesothelioma 10.8 GAS5 MET PVT1
24 childhood multilocular cystic kidney neoplasm 10.8
25 lymphoma, hodgkin, classic 10.8 MIR20A MIR21 PVT1
26 prostate disease 10.7 GAS5 H19 MALAT1 MEG3
27 gastrointestinal system cancer 10.7 H19 HOTAIR MALAT1 MET
28 pituitary adenoma 10.7 H19 HOTAIR MALAT1 MEG3
29 ovarian epithelial cancer 10.7 H19 HOTAIR MALAT1 MEG3
30 hemihyperplasia, isolated 10.7 H19 KCNQ1OT1
31 malignant glioma 10.7 GAS5 H19 MALAT1 MEG3
32 astrocytoma 10.7 H19 HOTAIR MIR21 PVT1
33 vulva squamous cell carcinoma 10.7 MALAT1 MEG3
34 gallbladder cancer 10.7 H19 HOTAIR MALAT1 MEG3
35 silver-russell syndrome 10.7 H19 KCNQ1OT1 MEG3
36 beckwith-wiedemann syndrome 10.7
37 von hippel-lindau syndrome 10.7
38 wilms tumor 1 10.7
39 denys-drash syndrome 10.7
40 perlman syndrome 10.7
41 wilms tumor 5 10.7
42 simpson-golabi-behmel syndrome 10.7
43 kidney hemangiopericytoma 10.7
44 transitional cell carcinoma 10.7
45 kidney sarcoma 10.7
46 kidney clear cell sarcoma 10.7
47 angiomatosis 10.7
48 tongue squamous cell carcinoma 10.7 MALAT1 MEG3 MIR21
49 liver cirrhosis 10.7 GAS5 HOTAIR MALAT1 MEG3
50 pancreatic ductal adenocarcinoma 10.6 H19 HOTAIR MALAT1 MIR21 PVT1

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Avastin 18 49 BEVACIZUMAB Genentech July 2009
3
Inlyta 18 49 AXITINIB Pfizer January 2012
4
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
6
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
7
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
8
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 555)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 5284616 6436030 46835353
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
6
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
7
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
8
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 284461-73-0 216239 406563
11
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
13
Zoledronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
15
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
16
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
17
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
18
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
19
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
20
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
22
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
23
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
24
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-67-6 938
27
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 98-92-0 936
28
Caffeine Approved, Nutraceutical Phase 4,Phase 1 58-08-2 2519
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 interferons Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1778)
# Name Status NCT ID Phase Drugs
1 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
2 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
3 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
6 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
8 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
10 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Completed NCT01266837 Phase 4 Everolimus
11 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
12 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
13 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4 Doxycycline;Placebo
14 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
17 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
18 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
19 Effects of Anesthesia on Immunity in Cancer Recruiting NCT03514550 Phase 4 Propofol;Sevoflurane
20 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
21 Study of Nivolumab for Advanced Cancers in India Recruiting NCT03444766 Phase 4 Nivolumab
22 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Recruiting NCT03323021 Phase 4
23 QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
24 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
25 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
26 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
27 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
28 Efficacy of IV Acetaminophen Versus Oral Acetaminophen Not yet recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
29 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
30 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
31 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
32 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
33 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
34 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
35 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
36 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
37 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
38 Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Completed NCT00416429 Phase 3 medroxyprogesterone
39 Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer Completed NCT00416871 Phase 3
40 AE-941 in Treating Patients With Metastatic Kidney Cancer Completed NCT00005995 Phase 3 shark cartilage extract AE-941
41 Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
42 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00018941 Phase 3
43 Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer Completed NCT00002473 Phase 3
44 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00005966 Phase 3 thalidomide
45 Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer Completed NCT00053807 Phase 3 fluorouracil
46 Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer Completed NCT00053820 Phase 3 fluorouracil
47 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
48 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Completed NCT00003126 Phase 3 Interleukin-2
49 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
50 Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Neoplasm 29
2 Renal Cancer 29

Anatomical Context for Kidney Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

19
The Kidney

MalaCards organs/tissues related to Kidney Cancer:

41
Kidney, Lung, Bone, Endothelial, Brain, Prostate, Testes

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 1159)
# Title Authors Year
1
A Study for the Detection of Kidney Cancer Using Fluorescence Emission Spectra and Synchronous Fluorescence Excitation Spectra of Blood and Urine. ( 29800712 )
2018
2
Updates to the Management of Kidney Cancer. ( 29784745 )
2018
3
Lenvatinib for the treatment of kidney cancer. ( 29737893 )
2018
4
Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. ( 29449090 )
2018
5
Kidney cancer: PDL1 as a biomarker in high-risk RCC. ( 29434371 )
2018
6
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. ( 29742094 )
2018
7
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. ( 29389967 )
2018
8
TGF-I^1 targets a microRNA network that regulates cellular adhesion and migration in renal cancer. ( 29079415 )
2018
9
Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer. ( 29424894 )
2018
10
BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. ( 29767721 )
2018
11
Kidney cancer in Saudi Arabia. A 25-year analysis of epidemiology and risk factors in a tertiary center. ( 29738004 )
2018
12
Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. ( 29801993 )
2018
13
Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation. ( 29325224 )
2018
14
Broadening the View of Germline Mutations in Kidney Cancer. ( 29978199 )
2018
15
The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. ( 29381020 )
2018
16
Recurrent renal cancer in Birt-Hogg-DubAc syndrome: A case report. ( 29223882 )
2018
17
The incidence of kidney cancer in Iran: a systematic review and meta-analysis. ( 29806587 )
2018
18
Kidney cancer: First-in-class HIF2I+ antagonist safe and effective. ( 29335652 )
2018
19
NICE recommends kidney cancer drug "likely to be less effective" than current treatments after price deal. ( 29449220 )
2018
20
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. ( 29368112 )
2018
21
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. ( 29877179 )
2018
22
Rapid intra-operative diagnosis of kidney cancer by ATR-IR spectroscopy of tissue smears. ( 29316381 )
2018
23
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29355171 )
2018
24
Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. ( 29783588 )
2018
25
Contemporary surgical outcomes of venous tumour thrombectomy managed with intraoperative Doppler ultrasound for kidney cancer. ( 29787368 )
2018
26
Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. ( 29911113 )
2018
27
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis. ( 29891937 )
2018
28
Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic. ( 29962849 )
2018
29
A Complex Cardiac Mass Originating from Interatrial Septum in a Patient with History of Kidney Cancer: A Case Report and Literature Review. ( 29955398 )
2018
30
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium. ( 29742093 )
2018
31
Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. ( 29331568 )
2018
32
HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. ( 29384723 )
2018
33
Kidney cancer in 2017: Challenging and refining treatment paradigms. ( 29335524 )
2018
34
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. ( 29977349 )
2018
35
PTEN in kidney cancer: A review and meta-analysis. ( 29408173 )
2018
36
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29358781 )
2018
37
Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes. ( 28793269 )
2017
38
A step towards predicting checkpoint inhibitor response in kidney cancer. ( 28759367 )
2017
39
Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. ( 27638770 )
2017
40
Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. ( 28503238 )
2017
41
SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. ( 28868352 )
2017
42
Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. ( 28798821 )
2017
43
Basic/Translational Science Survey Section: Kidney Cancer. ( 28340689 )
2017
44
Hereditary Kidney Cancer Syndromes and Surgical Management of the Small RenalA Mass. ( 28411908 )
2017
45
Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. ( 29266437 )
2017
46
A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. ( 28454375 )
2017
47
Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer. ( 28753845 )
2017
48
Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations. ( 28358873 )
2017
49
Kidney cancer: Tracking and therapy selection using ctDNA. ( 28467397 )
2017
50
Detecting circulating tumor DNA in renal cancer: An open challenge. ( 28214514 )
2017

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6
(show all 18)
# Gene Variation Type Significance SNP ID Assembly Location
1 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
2 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh38 Chromosome 7, 116783360: 116783360
3 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
4 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh38 Chromosome 7, 116777410: 116777410
5 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh37 Chromosome 7, 116423413: 116423413
6 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh38 Chromosome 7, 116783359: 116783359
7 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh37 Chromosome 7, 116417463: 116417463
8 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh38 Chromosome 7, 116777409: 116777409
9 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh37 Chromosome 7, 116423474: 116423474
10 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh38 Chromosome 7, 116783420: 116783420
11 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh37 Chromosome 1, 11169361: 11169361
12 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh38 Chromosome 1, 11109304: 11109304
13 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh37 Chromosome 1, 11182179: 11182179
14 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh38 Chromosome 1, 11122122: 11122122
15 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh37 Chromosome 1, 11184573: 11184573
16 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
17 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh37 Chromosome 1, 11217299: 11217299
18 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh38 Chromosome 1, 11157242: 11157242

Cosmic variations for Kidney Cancer:

9
(show top 50) (show all 242)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 19
2 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 19
3 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma c.548C>A p.S183* 3:10149871-10149871 19
4 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 19
5 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 19
6 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 19
7 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma c.266T>A p.L89H 3:10142113-10142113 19
8 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 19
9 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma c.234T>G p.N78K 3:10142081-10142081 19
10 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma c.500G>A p.R167Q 3:10149823-10149823 19
11 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma c.482G>A p.R161Q 3:10149805-10149805 19
12 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma c.341-2A>T p.? 3:10146512-10146512 19
13 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma c.217C>T p.Q73* 3:10142064-10142064 19
14 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 19
15 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 19
16 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 19
17 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 19
18 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 19
19 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 19
20 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 19
21 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 19
22 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 19
23 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 19
24 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 19
25 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 19
26 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 19
27 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 19
28 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 19
29 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 19
30 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 19
31 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 19
32 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 19
33 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 19
34 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 19
35 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 19
36 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 19
37 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 19
38 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 19
39 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 19
40 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 19
41 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 19
42 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 19
43 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 19
44 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 19
45 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 19
46 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 19
47 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 19
48 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 19
49 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 19
50 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 19

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MET MIR17 MIR200B MIR200C MIR20A MIR21
2 10.03 HOTAIR MEG3

GO Terms for Kidney Cancer

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.76 MIR17 MIR200B MIR20A MIR21
2 miRNA mediated inhibition of translation GO:0035278 9.58 MIR17 MIR20A MIR21
3 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.52 MIR20A MIR21
4 positive regulation of endothelial cell differentiation GO:0045603 9.51 MIR200C MIR21
5 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.49 MIR17 MIR20A
6 regulation of protein kinase B signaling GO:0051896 9.48 MIR21 MTOR
7 positive regulation of metalloendopeptidase activity GO:1904685 9.43 MIR17 MIR21
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.43 MIR17 MIR20A MIR21
9 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR17 MIR21
10 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.32 MET MIR21
11 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.16 MIR17 MIR20A
12 negative regulation of stress fiber assembly GO:0051497 9.13 MET MIR20A MIR21
13 gene silencing by miRNA GO:0035195 9.1 MIR17 MIR191 MIR200B MIR200C MIR20A MIR21

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR17 MIR200B MIR200C MIR20A MIR21

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....